Fibroblast Growth Factor-2 (FGF-2) Expression in Pterygia Using Cell Spot Arrays.

FGF cytology growth factors image analysis pterygia

Journal

Vision (Basel, Switzerland)
ISSN: 2411-5150
Titre abrégé: Vision (Basel)
Pays: Switzerland
ID NLM: 101733282

Informations de publication

Date de publication:
22 Sep 2022
Historique:
received: 06 08 2022
revised: 18 09 2022
accepted: 20 09 2022
entrez: 24 10 2022
pubmed: 25 10 2022
medline: 25 10 2022
Statut: epublish

Résumé

Fibroblast growth factor (FGF) is a main regulator of cell differentiation, cell migration and angiogenesis in normal and abnormal conjunctiva epithelia, but specific mechanisms of its aberrant expression are yet to be investigated. In the present study, we investigated FGF-2 protein expression within several pterygia. Using a liquid-based cytology assay, we obtained cell specimens from pterygia and healthy tissues directly from patients. A combination of immunocytochemistry followed by digital image analysis showed significant overexpression of FGF-2 in all the examined pterygia. In 30/60 (50%) cases there were high levels of staining intensity, whereas in the remaining 30/60 (50%) cases there were moderate levels of expression. FGF-2 levels of the control group were significantly lower in comparison with the pterygia group. There was no significant correlation between FGF-2 levels and either sex or location of the pterygium. FGF-2 levels had a significant correlation with morphological characteristics of the pterygia. More specifically, FGF-2 levels were significantly higher in the pterygia with a fleshy morphology. Interestingly, recurrent lesions demonstrated high expression levels. An overexpression of FGF-2 has been observed frequently in pterygia, where it may play a crucial role in determining the lesion's progression. FGF-2 upregulation correlates with the morphology of pterygia and its tendency to recur. Cell spot analysis based on liquid-based cytology is a simple, yet effective, method for detecting a broad spectrum of protein markers and could be useful in analyzing potential pterygia patient samples.

Identifiants

pubmed: 36278670
pii: vision6040058
doi: 10.3390/vision6040058
pmc: PMC9589943
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Br J Ophthalmol. 2010 Jul;94(7):815-20
pubmed: 19515643
Nat Rev Mol Cell Biol. 2013 Mar;14(3):166-80
pubmed: 23403721
Int J Mol Med. 2009 Apr;23(4):439-47
pubmed: 19288018
Wiley Interdiscip Rev Dev Biol. 2015 May-Jun;4(3):215-66
pubmed: 25772309
Int Immunopharmacol. 2021 Sep;98:107921
pubmed: 34225235
Curr Eye Res. 2000 Apr;20(4):325-34
pubmed: 10806447
Graefes Arch Clin Exp Ophthalmol. 1998 Sep;236(9):702-8
pubmed: 9782432
EMBO Mol Med. 2019 Feb;11(2):
pubmed: 30610113
Acta Histochem. 1996 Apr;98(2):195-201
pubmed: 8739304
Semin Ophthalmol. 2016;31(6):567-83
pubmed: 25415268
Eye Contact Lens. 2010 Sep;36(5):290-5
pubmed: 20724855
Oncogene. 2014 Jun 26;33(26):3411-21
pubmed: 23975425
Curr Eye Res. 2013 Dec;38(12):1191-7
pubmed: 24047084
Oncotarget. 2017 Nov 9;8(62):105630-105636
pubmed: 29285278
Genomics. 2000 Oct 15;69(2):275-9
pubmed: 11031111
Int J Ophthalmol. 2018 May 18;11(5):797-801
pubmed: 29862178
Curr Eye Res. 2022 Jul;47(7):1003-1008
pubmed: 35322737
Burns Trauma. 2022 Mar 23;10:tkac005
pubmed: 35350443
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2154-63
pubmed: 10892857
J Biol Chem. 2006 Nov 17;281(46):35208-16
pubmed: 17005551
Signal Transduct Target Ther. 2020 Sep 2;5(1):181
pubmed: 32879300
Front Med (Lausanne). 2022 May 06;9:803016
pubmed: 35602513
Surv Ophthalmol. 2018 Sep - Oct;63(5):719-735
pubmed: 29551597
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4514-4523
pubmed: 28873177
Histol Histopathol. 2015 Mar;30(3):311-20
pubmed: 25314135
Cancer Metastasis Rev. 2015 Sep;34(3):479-96
pubmed: 26224133
Ocul Surf. 2014 Apr;12(2):112-9
pubmed: 24725323
Nat Cell Biol. 2004 Jan;6(1):38-44
pubmed: 14688794
J Mol Med (Berl). 2022 Jun;100(6):847-860
pubmed: 35484303
Expert Opin Ther Targets. 2015;19(10):1361-77
pubmed: 26125971
Arch Ophthalmol. 1997 Oct;115(10):1235-40
pubmed: 9338666
Int J Mol Sci. 2022 Mar 30;23(7):
pubmed: 35409195
Int J Immunopathol Pharmacol. 2012 Jul-Sep;25(3):607-15
pubmed: 23058011
Endocrine. 2022 Sep;77(3):411-418
pubmed: 35583844
Int J Ophthalmol. 2017 Jun 18;10(6):973-981
pubmed: 28730091
Histol Histopathol. 2019 Aug;34(8):917-929
pubmed: 30821336
Invest Ophthalmol Vis Sci. 1987 Nov;28(11):1838-43
pubmed: 3667155

Auteurs

Stylianos Mastronikolis (S)

Department of Ophthalmology, Medical School, University of Patras, 26504 Patras, Greece.

Evangelos Tsiambas (E)

Department of Cytology, 417 Veterans Army Hospital (NIMTS), 11521 Athens, Greece.

Konstantinos Kagkelaris (K)

Department of Ophthalmology, Medical School, University of Patras, 26504 Patras, Greece.

Marina Pagkalou (M)

Department of Chemistry, University of Crete, 71500 Voutes, Greece.

Panagiotis Plotas (P)

Department of Primary Health Care, School of Health Rehabilitation Sciences, University of Patras, 26504 Patras, Greece.

Sofianiki Mastronikoli (S)

Brighton and Sussex Medical School, University of Sussex, Brighton BN1 9PX, UK.

Dimitrios Roukas (D)

Department of Cytology, 417 Veterans Army Hospital (NIMTS), 11521 Athens, Greece.

Constantinos D Georgakopoulos (CD)

Department of Ophthalmology, Medical School, University of Patras, 26504 Patras, Greece.

Classifications MeSH